Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 3-Year EBITDA Growth Rate is 38.80% as of Dec. 2025. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, SinoMab BioScience ranks better than 77.46% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 38.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of SinoMab BioScience was 38.80% per year. The lowest was -55.90% per year. And the median was -5.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SinoMab BioScience 3-Year EBITDA Growth Rate Related Terms
FRA:4VF vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, SinoMab BioScience's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 38.80% mean?
SinoMab BioScience (FRA:4VF) has a 3-Year EBITDA Growth Rate of 38.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #254 out of 1127 companies in the Biotechnology industry, placing it in the top 22.5%.
Is SinoMab BioScience's 3-Year EBITDA Growth Rate too high?
SinoMab BioScience's current 3-Year EBITDA Growth Rate is 38.80%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. SinoMab BioScience's value of 38.80% is 165.8% above this industry median. Based on the distribution chart, SinoMab BioScience ranks #254 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #254 out of 1127 companies for 3-Year EBITDA Growth Rate. This places SinoMab BioScience in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. SinoMab BioScience's value of 38.80% is 165.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SinoMab BioScience's current 3-Year EBITDA Growth Rate of 38.80% is 165.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SinoMab BioScience and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current 3-Year EBITDA Growth Rate is 38.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current 3-Year EBITDA Growth Rate of 38.80%. The current 3-Year EBITDA Growth Rate is 38.80% and 165.8% above the Biotechnology industry median of 14.60. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current 3-Year EBITDA Growth Rate is 38.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
